In this issue of JAMA Internal Medicine, van der Geest et al1 present a systematic review and meta-analysis of the diagnostic accuracy of symptoms, signs, and laboratory tests for giant cell arteritis (GCA). Their comprehensive review of 68 studies with 14 037 patients provides updated guidance for clinicians who assess the probability that a patient has GCA. This estimation drives decisions about temporal artery biopsy and glucocorticoid administration that include considerations of timing and logistics, patient comorbidities, coordination with consultants, and adverse effects of treatment. Giant cell arteritis is a disease that has no reference or “gold” standard test, yet once affixed to the record, it can set off a complicated diagnostic and therapeutic cascade.